Novartis Cancer, Heart Drugs Disappoint as Company Lifts Targets |
Finance
|
sreda, 30. oktober 2024 ob 05:00 |
While Novartis provided an optimistic take on 2024, the lack of commentary on 2025 “may disappoint,” Bloomberg Intelligence analyst John Murphy said in a note
|